Frontiers in Clinical Drug Research-Hematology

Volume 2

by

Atta-ur-Rahman FRS

DOI: 10.2174/97816810818161160201
eISBN: 978-1-68108-181-6, 2016
ISBN: 978-1-68108-182-3
ISSN: 2352-3239 (Print)



Recommend this eBook to your Library

Indexed in: EBSCO.

Frontiers in Clinical Drug Research – Hematology is an eBook series that brings...[view complete introduction]

Table of Contents

Preface

- Pp. i

Atta-ur-Rahman

Download Free

List of Contributors

- Pp. iii

Atta-ur-Rahman

Download Free

Molecular and Therapeutic Clues in Chronic Myeloid Leukemia

- Pp. 3-80 (78)

Gabriella Marfe, Giovanna Mirone, Arvind Shukla and Carla Di Stefano

View Abstract Purchase Chapter

Bispecific and Multivalent Antibodies - New Swords to Combat Hematological Malignancies

- Pp. 81-131 (51)

Michael Stanglmaier and Juergen Hess

View Abstract Purchase Chapter

Natural Killer Cells as an Immune Cell Therapy Option for Bone Marrow Transplantation in Hematological Malignancies: Implications for New Therapies Based on Lipid Transfer and Cell-to- Cell Communication

- Pp. 132-175 (44)

Beatriz Martín-Antonio, Nuria Martínez-Cibrian, Alvaro Urbano- Ispizua and Ciril Rozman

View Abstract Purchase Chapter

Nanoparticles in Health and Disease: An Overview of Nanomaterial Hazard, Benefit and Impact on Public Health Policy - Current State and Outlook

- Pp. 176-255 (80)

Stanislav Janousek, Dagmar Jirova, Kristina Kejlova and Marketa Dvorakova

View Abstract Purchase Chapter

Monoclonal Antibodies in Lymphoma

- Pp. 256-299 (44)

Esmeralda Chi-yuan Teo and Colin Phipps

View Abstract Purchase Chapter

Subject Index

- Pp. 300-305 (6)

Atta-ur-Rahman

Download Free

Preface

Volume 2 of Frontiers in Clinical Drug Research-Hematology comprises of five comprehensive chapters written by eminent experts covering recent advances in the treatment of lymphoma, bone marrow transplantation, chronic myeloid leukemia and various hematological malignancies.

In the first chapter Marfe and colleagues reviewed the literature related to molecular biology of chronic myeloid leukemia with particular emphasis on agents that target at the molecular level and their resistance mechanisms in order to combat disease.

The treatment of cancer by targeted biologics such as monoclonal antibodies has been shown to be a promising approach. According to recent studies, bi- and multi-specific antibodies have been found to be more effective in fighting against tumor cells. In the second chapter of this eBook, Stanglmaier and Hess present an overview of the current development of bi- and multi-specific antibodies for treatment of B-cell malignancies.

In the third chapter, Martín-Antonio et al., highlight the strengths and weaknesses of Natural Killer cells in fighting Multiple Myeloma and hematological malignancies. They also propose certain guidelines for the development of future trials.

Janousek and colleagues, in chapter 4, shed light on a potentially revolutionary topic i.e., nanoparticles and nanomaterials. They review the role of nanoparticles in the management of hematological and malignant disorders. Phipps and Teo in the last chapter have drawn attention to the importance of new advancements in delivery methods of Monoclonal Antibodies to target the antigens that are present on lymphoma cells.

I would like to acknowledge the efforts of all the contributors for their outstanding contributions. I am also thankful to the team of Bentham Science Publishers, especially Dr. Faryal Sami and Mr. Shehzad Naqvi led by Mr. Mahmood Alam, Director Bentham Science Publishers for their efforts.

Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
Cambridge
UK

List of Contributors

Editor(s):
Atta-ur-Rahman FRS
Kings College
University of Cambridge
UK




Contributor(s):
Alvaro Urbano-Ispizua
Department of Hematology, Hospital Clinic, IDIBAPS
Barcelona
Spain
/
Josep Carreras Leukaemia Research Institute
Barcelona
Spain


Arvind Shukla
School of Biotechnology and Bioinformatics, D.Y. Patil University
Plot No.50, Sector- 15, C.B.D. Belapur, Navi Mumbai, 400614,
Maharastra
India


Beatriz Martín-Antonio
Department of Hematology, Hospital Clinic, IDIBAPS
Barcelona
Spain
/
Josep Carreras Leukaemia Research Institute
Barcelona
Spain


Carla Di Stefano
Department of Hematology, "Tor Vergata" University, Viale Oxford 81, 00133
Rome
Italy


Ciril Rozman
University of Barcelona
Barcelona
Spain
/
Josep Carreras Leukaemia Research Institute
Barcelona
Spain


Colin Phipps
Department of Hematology, Singapore General Hospital
Singapore


Dagmar Jirova
Center of Toxicology and Health Safety
National Institute of Public Health, Srobarova 48, 100 42
Instituto Nacional de Câncer (INCA)
Prague, Czech Republic


Gabriella Marfe
Department of Biochemistry and Biophysics
Second University of Naples, via De Crecchio 7
Naples 80138
Italy


Giovanna Mirone
Department of Medical Oncology B
Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144
Rome, Italy


Juergen Hess
Lerchenstraße 3, D-85368
Moosburg
Germany


Kristina Kejlova
Center of Toxicology and Health Safety
National Institute of Public Health, Srobarova 48, 100 42
Prague
Czech Republic


Marketa Dvorakova
Center of Toxicology and Health Safety
National Institute of Public Health, Srobarova 48, 100 42
Prague
Czech Republic


Michael Stanglmaier
Lerchenstraße 3, D-85368
Moosburg
Germany


Nuria Martínez-Cibrian
Department of Hematology, Hospital Clinic, IDIBAPS
Barcelona
Spain
/
Josep Carreras Leukaemia Research Institute
Barcelona
Spain


Stanislav Janousek
Center of Toxicology and Health Safety
National Institute of Public Health, Srobarova 48, 100 42
Prague
Czech Republic




Advertisement



Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science